The US Food and Drug Administration (FDA) has approved AbbVie's VYALEV (foscarbidopa and foslevodopa) to treat motor ...

Sage said in an SEC filing that it expects a non-recurring charge tied to the workforce reduction of $26 million to $28 ...

Performance Zone, a gym in Morehead City, offers a program aimed at improving the lives of individuals battling Parkinson's ...

The FDA on Thursday approved an injectable drug that eased Parkinson's disease symptoms and improved motor fluctuations in ...

New OU program allows graduates to bypass FAA air traffic control academy ...

Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for motor ...

Annovis faces financial challenges and questionable efficacy in Alzheimer's and Parkinson's trials, risking poor stock ...

AbbVie also sells a continuous-delivery system for Parkinson's branded as Duopa that pumps a levodopa-carbidopa gel directly ...

After two previous failed attempts with the FDA, AbbVie now has one more offering in its lineup — a critical step as it ...

Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.

AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...

Dementia in Parkinson disease occurs less frequently or much later in the disease course than previously expected.